Matchpoint: a toolkit to create covalent therapies for immunology

With $100 million in early funding from VCs, Matchpoint will deploy a chemistry and computational toolkit to advance a pipeline of covalent small molecules against validated but difficult targets, initially in immunology.

The funding includes a new $70 million series A led by Sanofi Ventures, as well as $30 million in seed capital from Atlas Venture and Access Biotechnology in November 2021. Atlas’ Bruce Booth is its chairman...